Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.
Please enable it in your browser's preferences.
You can visit our support center if you're having problems.
We recommend upgrading to the latest
Page load failed
Please check your internet connection and refresh the page. You might also try disabling any ad blockers.